CV Lattes
ORCID
Google Scholar Citations
Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. Escola Paulista de Medicina (EPM) (Institutional affiliation from the last research proposal) Birthplace: Brazil
Full Professor at the Paulista School of Medicine, Federal University of São Paulo (EPM-UNIFESP). He was the coordinator of the National Institute of Gene Therapy (2023-2024). He served as president of the Brazilian Association of Cellular and Gene Therapy (ABTCEL-GEN) from 2019 to 2023, and as vice-president from 2019 to 2021. Co-founder of the Interdisciplinary Center for Gene Therapy (CINTERGEN) at UNIFESP, he was the director of this center from its foundation in 2004 until 2010. During this period, he developed the first vector used for clinical gene therapy in Brazil.He was a member of the Advanced Therapies Technical Chamber of ANVISA (Brazilian Health Regulatory Agency) and CTNBio (National Biosafety Commission), where he contributed to the development of regulations for the use of gene therapy in Brazil. He has represented specialists in the National Network of Experts in Advanced Therapies (RENETA-ANVISA) since its formation.He holds a degree in Chemistry, a Master's and Ph.D. in Biochemistry from the University of São Paulo, and a Habilitation in Biophysics from UNIFESP. He completed his post-doctoral training in Gene Therapy at the University of Washington, Seattle, USA, from 1992 to 1994, and has been dedicated to this field in Brazil ever since. His main research areas include gene therapy for ischemic and genetic diseases, cancer, and DNA vaccines.Google Scholar: https://scholar.google.com.br/citations?user=j9dfSOEAAAAJhl=en (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Peripheral arterial disease affects millions of people worldwide, with an increasing impact due to the aging population and the rise of obesity. Elderly, obese, and diabetic patients face difficulties in treatment through conventional methods, highlighting the importance of minimally invasive alternative therapies. This project's primary goal is to investigate the role of ANXA1 (Annexin A…
The main objective of the current thematic project of FAPESP is to study the relationship between the colony- stimulating factors (CSFs) and the type of monocytes/macrophages recruited under normoxia and hypoxia, and to elaborate procedures of gene and cell therapy of ischemic diseases by recruiting more proresolutive macrophages or by implanting proresolutive macrophages genetically engi…
Peripheral arterial disease affects millions of people every year and compromises the quality of life and shortens the life expectancy of these patients. The non-healing ulcer and strong chronic pain are the main symptoms of this disease in advanced stage that occurs due to tissue hypoperfusion and can lead to amputation of the affected limb and death. In the ischemic limb a constant infl…
The carcinoembryonic antigen (CEA) is a tumor marker for cancers of epithelial origin, which is expressed during embryonic life and is present in some normal adult tissues: consequently, CEA is recognized as a self-antigen by the immune system. The replacement of antigen for immunization by anti-idiotypic antibody has been considered a promising strategy to break tolerance in some types o…
(Only some records are available in English at this moment)
Peripheral arterial disease is characterized by the narrowing of peripheral vessels, and can advance to Critical Limb Ischemia (CLI). Within a year, 25% of patients die and 30% suffer amputation due to the lack of therapeutic options. The two main pathophysiological changes that occur in ischemic tissue are the decrease in blood flow and the increase in inflammation, which need to be addr…
The critical limb ischemia (CLI) is characterized by the narrowing of arteries from lower limbs. It is being estimated that 25% of patients diagnosticated with CLI will die and others 30% will receive amputation within a year. The CLI available treatments are limited due co-morbidities and advanced age of patients, thus, it is necessary to develop new alternative therapies. Among these, t…
The main targets of thematic project are the modulation of macrophages by CSFs to promote the formation of M2 macrophages. These cells produce a series of growth factors, which promote vessel formation and remodeling, and myogenesis in ischemic and inflamed skeletal muscle. The main oxygen sensor in cells is the proline hydroxylase of HIF (Hypoxia Inducible Factor), which is called the PH…
(Only some records are available in English at this moment)
Interest in the development of RNA-based therapeutics has increased in recent years with demonstrations of high efficacy of Covid-19 vaccines. The capacity for rapid development and relatively low cost for production in large scale are main advantages. The mRNA instability and inefficient in vitro e in vivo delivery of mRNA have been improved significantly by chemical alterations, improve…
Peripheral arterial disease (PAD) is a circulatory disorder caused by atherosclerosis, which affects millions of people every year. In the advanced stage of PAD, this disease evolves to critical limb ischemia (CLI) which severely affects the limb's blood circulation, causing pain at rest and nonhealing wounds. Therefore, the promotion of angiogenesis and control of inflammation should fav…
Fibrosis is a major acquired sequel after muscle. The fibrotic process prevents proper muscle contraction and can lead to muscle contractures and chronic pain. In more severe injuries, in which healing occurs slowly, fibrosis prevents the proper muscle contraction and can lead to chronic pain and muscle contractures. In addition to functional loss, scar tissue tends to suffer further inju…
(Only some records are available in English at this moment)
| 1 / 1 | Ongoing grants |
| 14 / 10 | Completed research grants |
| 34 / 19 | Completed scholarships in Brazil |
| 4 / 4 | Completed scholarships abroad |
| 53 / 34 | All research grants and scholarships |
| Associated processes | |